Drug Profile
Niraparib companion diagnostic - Myriad
Alternative Names: GlaxoSmithKline; myChoice HRD - niraparib; myChoice HRD CDx; Niraparib - myChoice HRDLatest Information Update: 25 Apr 2022
Price :
$50
*
At a glance
- Originator Myriad Genetics
- Developer GlaxoSmithKline; GSK; Myriad Genetics
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Ovarian cancer
- Discontinued Fallopian tube cancer; Peritoneal cancer
Most Recent Events
- 25 Apr 2022 Discontinued - Preregistration for Fallopian tube cancer (Diagnosis, Second-line therapy or greater) in USA (unspecified route) (Myriad genetics website, April 2022)
- 25 Apr 2022 Discontinued - Preregistration for Peritoneal cancer (Diagnosis, Second-line therapy or greater) in USA (unspecified route) (Myriad genetics website, April 2022)
- 25 Apr 2022 No development reported - Preregistration for Ovarian cancer (Diagnosis) in Japan (unspecified route) (Myriad genetics website, April 2022)